Table 5.
Comparison of liver studies at admission between survivors and deceased elderly with COVID-19.
| Variables * | Normal Range | Survivors (n = 262) | Deceased (n = 54) | p-Value |
|---|---|---|---|---|
| Fasting glucose (mmol/L) | 60–125 | 96 (36.6%) | 29 (53.7%) | 0.019 |
| ALT (U/L) | 7–35 | 68 (32.4%) | 31 (57.4%) | <0.001 |
| AST (U/L) | 10–40 | 97 (37.0%) | 36 (66.7%) | <0.001 |
| ALP (U/L) | 40–130 | 101 (38.5%) | 30 (55.6%) | 0.020 |
| Serum albumin (g/dL) | 3.4–5.4 | 64 (24.4%) | 25 (46.3%) | 0.001 |
| Total proteins (g/dL) | 6.0–8.3 | 67 (25.6%) | 23 (42.6%) | 0.011 |
| Total bilirubin (g/dL) | 0.3–1.2 | 60 (22.9%) | 18 (33.3%) | 0.105 |
| GGT (U/L) | 0–30 | 63 (24.0%) | 20 (37.0%) | 0.048 |
| LDH (U/L) | 140–280 | 75 (28.6%) | 24 (44.4%) | 0.022 |
| PT (seconds) | 11.0–13.5 | 71 (27.1%) | 21 (38.9%) | 0.082 |
| APTT (seconds) | 30–40 | 63 (24.0%) | 19 (35.2%) | 0.089 |
| FIB-4 | 1.45–3.25 | 84 (32.1%) | 28 (51.9%) | 0.005 |
| NFS | <−1.5 | 70 (26.7%) | 22 (40.7%) | 0.038 |
| APRI | 0.5–1.5 | 72 (27.5%) | 25 (46.3%) | 0.006 |
* Data reported as n (%) outside the normal range and calculated using Chi-square test and Fisher’s exact unless specified differently; ALT—alanine aminotransferase; AST—aspartate aminotransferase; ALP—alkaline phosphatase; GGT—gamma glutamyl transpeptidase; LDH—lactate dehydrogenase; PT—prothrombin time; APTT—activated partial thromboplastin clotting time; FIB-4—Fibrosis-4 score; NFS—nonalcoholic fatty liver disease fibrosis score; APRI—AST to platelet ratio index.